Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • Lamotrigine: High-Purity Sodium Channel Blocker for Epile...

    2026-02-18

    Lamotrigine: High-Purity Sodium Channel Blocker for Epilepsy & CNS Research

    Executive Summary: Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) is a high-purity anticonvulsant and sodium channel blocker, chemically stable and suitable for in vitro sodium channel blockade assays (Hu et al., 2025, DOI). The compound exhibits an IC50 of 240 μM in human platelets and 474 μM in rat synaptosomes, with >99.7% purity confirmed by HPLC/NMR (APExBIO). Its molecular formula is C9H7Cl2N5 (MW 256.09), and it is insoluble in water but dissolves in DMSO (≥12.3 mg/mL) and ethanol (≥2.18 mg/mL) under gentle warming. Lamotrigine is a reference compound in blood-brain barrier (BBB) and CNS permeability models, facilitating rapid and reproducible screening. Its dual action on sodium channels and 5-HT signaling supports studies in epilepsy, cardiac arrhythmia, and CNS drug delivery (Matrix Protein, 2024).

    Biological Rationale

    Lamotrigine is chemically defined as 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, designed to target sodium channel signaling pathways. Its primary role is to block voltage-gated sodium channels, reducing neuronal excitability and stabilizing membranes. By inhibiting serotonin (5-HT) signaling, lamotrigine modulates neurotransmitter release and synaptic plasticity, mechanisms relevant to epilepsy, cardiac arrhythmias, and CNS disorders. The compound's high purity and solubility parameters ensure consistent dosing and reproducible results in both in vitro and in vivo research workflows (Decanoyl-RVKR-CMK, 2024). Lamotrigine’s robust chemical stability (recommended storage at -20°C) further underpins its value in extended experimental series.

    Mechanism of Action of Lamotrigine

    Lamotrigine primarily acts as a sodium channel blocker. It binds to the inactivated state of voltage-gated sodium channels, reducing sustained high-frequency firing of neurons. This action is quantified by IC50 values of 240 μM (human platelets) and 474 μM (rat brain synaptosomes) under standard assay conditions (pH 7.4, 37°C). Lamotrigine also inhibits serotonin (5-HT) signaling, impacting both neurotransmission and neurovascular modulation. Its dual action distinguishes it from other anticonvulsants, enabling unique applications in epilepsy-induced arrhythmia and BBB permeability studies. The compound’s efficacy and specificity have been validated in standardized in vitro sodium channel blockade assays (Matrix Protein, 2024), making it a reference agent in mechanistic and translational research.

    Evidence & Benchmarks

    • Lamotrigine demonstrates high purity (>99.7%) as validated by HPLC and NMR, ensuring batch-to-batch reproducibility (APExBIO).
    • The compound exhibits an IC50 of 240 μM in human platelet sodium channel assays (buffered at pH 7.4, 37°C) (Hu et al., 2025).
    • Solubility in DMSO is at least 12.3 mg/mL and in ethanol ≥2.18 mg/mL under gentle warming and ultrasonic agitation (APExBIO).
    • In vitro BBB permeability models (LLC-PK1-MOCK/MDR1) reliably predict brain distribution and passive/efflux properties for lamotrigine-class compounds (Hu et al., 2025).
    • Lamotrigine’s sodium channel blockade has been correlated with reduced seizure activity and cardiac sodium current modulation in preclinical models (Alpha-1-Antitrypsin Fragment, 2024).
    • Recommended storage is at -20°C, with solution stability maintained by avoiding long-term storage (>7 days) (APExBIO).

    Applications, Limits & Misconceptions

    Lamotrigine is widely used in:

    • Epilepsy research: as a benchmark sodium channel blocker for in vitro and ex vivo studies.
    • Cardiac sodium current modulation: for arrhythmia pathway exploration.
    • Blood-brain barrier permeability assays: in high-throughput CNS drug screening workflows (Hu et al., 2025).
    • Serotonin (5-HT) signaling inhibition: to dissect neurotransmitter-specific mechanisms.

    For detailed, scenario-driven optimization in sodium channel and 5-HT inhibition assays, see Lamotrigine (SKU B2249): Optimizing Sodium Channel and Serotonin Assays. This article expands on solubility optimization and vendor selection, complementing the present focus on CNS and BBB workflows.

    Common Pitfalls or Misconceptions

    • Lamotrigine is not water-soluble; attempts to dissolve in aqueous buffers result in precipitation and assay variability.
    • Long-term storage of prepared solutions (>7 days) leads to degradation and loss of potency.
    • Lamotrigine’s efficacy as a sodium channel blocker is concentration-dependent; sub-IC50 exposures yield incomplete channel inhibition.
    • It is not a universal serotonin inhibitor; its 5-HT inhibition is modest and context-specific compared to selective 5-HT antagonists.
    • BBB permeability data derived from non-validated in vitro models may not reflect in vivo brain distribution without rigorous controls (Hu et al., 2025).

    Workflow Integration & Parameters

    For optimal results, use lamotrigine at concentrations bracketed around its IC50 (e.g., 100–500 μM) in sodium channel assays. Dissolve in DMSO or ethanol, ensuring complete dissolution via gentle warming or sonication. Avoid precipitation by adding to aqueous buffers only after dilution to working concentrations. Store solid at -20°C and limit solution storage to less than 7 days. For BBB and CNS drug screening, integrate lamotrigine as a positive control in LLC-PK1-MOCK/MDR1 Transwell systems, benchmarking permeability coefficients (Papp) and efflux ratios against validated standards (Hu et al., 2025).

    To extend molecular insights into sodium channel blockade and 5-HT inhibition—including structure–activity relationships and translational assay optimization—see Lamotrigine: Molecular Insights into Sodium Channel Blockade. This resource provides additional mechanistic context not covered in the present application-focused review.

    Conclusion & Outlook

    Lamotrigine, supplied by APExBIO, is a high-purity, reproducible reference compound for sodium channel blockade and serotonin inhibition in CNS and cardiac research. Its validated solubility and stability parameters support robust in vitro and BBB permeability workflows. The integration of lamotrigine into preclinical screening panels enables researchers to dissect sodium channel and 5-HT signaling mechanisms with confidence. Future work may further refine structure–activity relationships and in vivo–in vitro correlations, accelerating CNS drug discovery.

    For product specifications and batch details, visit the Lamotrigine product page. For advanced workflow integration in epilepsy and BBB research, Lamotrigine: Applied Workflows in Epilepsy and BBB Research clarifies assay design and troubleshooting beyond the scope of this article.